Howe & Rusling’s Cytokinetics CYTK Stock Holding History

Howe & Rusling’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-280	Closed	-$3K	–	823
2020 Q1	$3K	Buy	280 +107	+62%	+$1.36K	﹤0.01%	562
2019 Q4	$2K	Hold	173	–	–	﹤0.01%	664
2019 Q3	$2K	Hold	173	–	–	﹤0.01%	672
2019 Q2	$2K	Sell	173 -15	-8%	-$145	﹤0.01%	653
2019 Q1	$2K	Sell	188 -30	-14%	-$221	﹤0.01%	663
2018 Q4	$1K	Buy	218 +70	+47%	+$514	﹤0.01%	725
2018 Q3	$1K	Hold	148	–	–	﹤0.01%	773
2018 Q2	$1K	Hold	148	–	–	﹤0.01%	731
2018 Q1	$1K	Sell	148 -19	-11%	-$163	﹤0.01%	846
2017 Q4	$1K	Hold	167	–	–	﹤0.01%	774
2017 Q3	$2K	Hold	167	–	–	﹤0.01%	739
2017 Q2	$2K	Hold	167	–	–	﹤0.01%	801
2017 Q1	$2K	Sell	167 -23	-12%	-$269	﹤0.01%	830
2016 Q4	$2K	Hold	190	–	–	﹤0.01%	851
2016 Q3	$2K	Buy	+190	New	+$1.98K	﹤0.01%	845

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

FCMI

Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Howe & Rusling's CYTK Position: Q2 2020 in Review

Howe & Rusling sold out of Cytokinetics (CYTK) in Q2 2020, closing a stake of 280 shares — an estimated $3K sold.

Howe & Rusling first reported a position in CYTK in Q3 2016 and held it in 15 quarters. The position peaked at $3K in Q1 2020. 158 funds tracked by Wall St. Rank hold CYTK as of Q2 2020.

Howe & Rusling reported no remaining Cytokinetics position as of Q2 2020 after selling out during the quarter.
Howe & Rusling sold 280 Cytokinetics shares in Q2 2020, an estimated $3K.
Howe & Rusling first reported a position in Cytokinetics in Q3 2016 and held it in 15 quarters.
Howe & Rusling's Cytokinetics position peaked at $3K in Q1 2020.
158 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2020.

Based on Howe & Rusling's 13F filing for Q2 2020, filed 15 Jul 2020.